NCT06180499View on ClinicalTrials.gov

Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

November 30, 2028

Study Completion Date

September 30, 2029

Conditions
Hematological MalignanciesRegulatory T Cell DepletionRelapse
Interventions
DRUG

T-reg depleted DLI

Treg depleted Donor Lymphocytes Infusion

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06180499 - Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion | Biotech Hunter | Biotech Hunter